Author: Customer Service

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease. The rolling NDA was initiated in April...

New vertical extends ROMA’s sustainable-finance mandate into energy-efficient, behind-the-meter-powered digital infrastructure; Company is evaluating a pipeline of distributed, sub-50 MW AI/HPC investment opportunities, subject to diligence, definitive documentation, and board approval. ROMA, HONG KONG, June 12, 2026 (GLOBE NEWSWIRE) — ROMA Green Finance Limited (Nasdaq: ROMA) (“ROMA” or the “Company”) today announced the establishment of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing (AI/HPC) infrastructure. The vertical extends the Company’s sustainable-finance and ESG advisory mandate into low-carbon, energy-efficient digital infrastructure. The vertical targets distributed, sub-50 MW compute assets paired with on-site behind-the-meter (BTM) power generation in low-cost energy...

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”). Each Unit will be offered at a price of $10,000 per Unit and is comprised of 200,000 common shares in the capital of the Company (the “Common Shares”) and 200,000 transferable share purchase warrants (the “Warrants”), resulting in the aggregate issuance of a minimum of 24,000,000 Common Shares and of a maximum of 44,000,000 Common Shares issued at a deemed price per share of $0.05 and a minimum of 24,000,000 Warrants and a maximum of 44,000,000 Warrants. Each Warrant entitles the holder to purchase a...

VANCOUVER, British Columbia, June 12, 2026 (GLOBE NEWSWIRE) — Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX.V: RYO) (OTC: RYOOF), announces shareholder approval for all matters at the AGM. All resolutions presented at Rio Silver’s annual general held on Friday, June 12, 2026, including the election of directors, the ratification of the appointment of its auditor for the year ended December 31, 2025, the reappointment of its current auditor and the approval of the company’s security based compensation plan. A total of 13,099,198 common shares or 22.24% of Rio Silver’s issued and outstanding common shares at the record date were represented in person or by proxy at the AGM. About Rio Silver Inc. Rio Silver is a Canadian exploration and development company with an large per cent of insider, friends and family ownership,...

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetesAccelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received TzieldParis, June 13, 2026. The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous (own) insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions. “We now have a novel therapy that targets the autoimmune...

Vancouver, BC, June 12, 2026 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) has granted an aggregate 47,013 stock options, exercisable at $0.71 per share and valid for a term of three years, and an aggregate 514,801 restricted share units, valid for a term between one to three years, to consultants and employees of the Company and its subsidiaries.  The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject to a statutory hold period of four months and one day from issuance, in addition to vesting provisions. Additionally, and further to the Company’s news release dated July 18, 2025, the Company has extended the marketing services provided by 45 Degrees, Inc. (“45 Degrees”) and Investment Publishing LLC (“Investment...